May 8, 2013
According to AbbVie, the Food and Drug Administration (FDA) has given its new hepatitis C drug regimen a breakthrough therapy designation, which will speed up its potential approval in the United States. The FDA's designation stems from clinical trial results, which have shown a high response rate to the combination therapy in which patients receive 1224 weeks of treatment with nearly one year of post-treatment follow-up.
05.06.2013; Samantha Bomkamp
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017|
|'Caring at Its Essence': HIV Nurses Recall Pivotal Moments With Patients|
|PrEP Prescriptions Rise Sharply, but Unequally, in New York City|
|How to Reverse Implicit Bias in HIV Care: 6 Steps to Take Today|
|In Their Words: Burdens of HIV Nursing Include Lack of Respect and Resources|
|Conversations With Federal HIV Leaders From the 2017 U.S. Conference on AIDS|